This inventor holds 2 USPTO granted patents and 2 published patent applications and 1 EPO patent. Top assignees: University System of Maryland, Regeneron Pharmaceuticals, Inc.. Active years: 2020-2025.
Company Filing History:
2 out of 2,023 
1 out of 1,477 
Years Active: 2020-2025
Title: Marja Puurunen: Innovator in Cardiovascular Research
Introduction
Marja Puurunen is a notable inventor based in Tarrytown, NY (US). She has made significant contributions to the field of cardiovascular research through her innovative work and patents. With a total of 2 patents, her research focuses on the B4GALT1 gene and its implications in cardiovascular conditions.
Latest Patents
Marja Puurunen's latest patents include groundbreaking work on B4GALT1 variants and their uses. These patents cover B4GALT1 cDNA variants and compositions, as well as methods for detecting the presence of these molecules. Her inventions also provide methods for modulating endogenous B4GALT1 genomic, mRNA, and cDNA nucleic acid molecules. Furthermore, they include techniques for ascertaining the risk of developing cardiovascular conditions by detecting the presence or absence of the variant B4GALT1 genomic, mRNA, and cDNA nucleic acid molecules. Additionally, her patents outline methods for treating cardiovascular conditions.
Career Highlights
Throughout her career, Marja has worked with prominent organizations such as Regeneron Pharmaceuticals, Inc. and the University System of Maryland. Her experience in these institutions has allowed her to collaborate with leading experts in the field and contribute to significant advancements in cardiovascular research.
Collaborations
Marja has collaborated with talented individuals, including May Montasser and Cristopher Van Hout. These partnerships have further enhanced her research and innovation in the field.
Conclusion
Marja Puurunen is a distinguished inventor whose work in cardiovascular research has led to valuable patents and collaborations. Her contributions continue to impact the scientific community and advance our understanding of cardiovascular conditions.